Malignant Thoracic Neoplasm

Ba/F3 cells expressing EML4-ALK variant 1 with ALK G1202R mutation were assessed for ceritinib sensitivity. Crizotinib was shown to confer significantly more potency than ceritinib (43-fold decrease i… (full text at CIViC)

PMID 24675041 · Friboulet et al., 2014 · Open in CIViC

The G1202R mutation in the EML4-ALK fusion was found to confer resistance to crizotinib in Ba/F3 cells.

PMID 22277784 · Katayama et al., 2012 · Open in CIViC

In an in vitro study, a Ba/F3 cell line expressing EML4-ALK fusion (a known sensitizing alteration to crizotinib) and an ALK G1202R co-mutation, demonstrated resistance to crizotinib treatment compare… (full text at CIViC)

PMID 24675041 · Friboulet et al., 2014 · Open in CIViC

The G1202R ALK mutation was found in a crizotinib-resistant ALK-rearranged NSCLC, and the mutant ALK fusion was further characterized in Ba/F3 cells. EML4-ALK variant 1 with G1202R mutation was expres… (full text at CIViC)

PMID 22277784 · Katayama et al., 2012 · Open in CIViC

This case report describes a 33 year-old non-smoker with no known exposure to asbestos who was diagnosed with stage IIIB malignant pleural mesothelioma. Panel next generation sequencing (NGS) of 520 g… (full text at CIViC)

PMID 32600123 · Hu et al., 2020 · Open in CIViC

Repeat biopsies were taken for 20 ALK-positive NSCLC patients, including 11 with pre- and post-lorlatinib biopsies. 19 of 20 patients received crizotinib and at least one second line ALK inhibitor. On… (full text at CIViC)

PMID 29650534 · Yoda et al., 2018 · Open in CIViC

This study analyzed patients with non small cell lung cancer (NSCLC) who were positive for EML4-ALK fusions (ALK+) and progressed on crizotinib monotherapy. One ALK+ patient harbored the common E6;A20… (full text at CIViC)

PMID 22235099 · Doebele et al., 2012 · Open in CIViC

2 out of 7 patients with an acquired resistance to crizotinib had a G1269A mutation. One of these patients also harbored a L1196M mutation. In vitro follow-up showed reduced crizotinib-induced ALK dep… (full text at CIViC)

PMID 23344087 · Kim et al., 2013 · Open in CIViC

A 33 year old male with no smoking history or known exposure to asbestos was diagnosed with malignant pleural mesothelioma (MPM). EML4::ALK was found using a panel of 520 genes in NGS, and the patient… (full text at CIViC)

PMID 32600123 · Hu et al., 2020 · Open in CIViC

This case report describes a 33 year-old non-smoker with no known exposure to asbestos who was diagnosed with stage IIIB malignant pleural mesothelioma. Panel next generation sequencing (NGS) of 520 g… (full text at CIViC)

PMID 32600123 · Hu et al., 2020 · Open in CIViC

In an in vitro study, a FL5.12 cell line expressing NPM1-ALK or EML4-ALK (known sensitizing alterations to crizotinib) and an ALK I1171S co-mutation, demonstrated resistance to crizotinib treatment (I… (full text at CIViC)

PMID 27009859 · Amin et al., 2016 · Open in CIViC

Case study describes a caucasian male (age 38) never smoker presenting with stage IV non-small cell lung cancer with an ALK rearrangement. Patient was given crizotinib and exhibited a partial response… (full text at CIViC)

PMID 25393796 · Ou et al., 2014 · Open in CIViC

Case-report of a patient with an acquired EML4::ALK L1152R mutation and resistance to crizotinib treatment. The L1152R variant was not present in the pre-crizotinib sample. A cell line model also show… (full text at CIViC)

PMID 21791641 · Sasaki et al., 2011 · Open in CIViC

CH5424802 treatment resulted in significant tumor regression in xenograft models produced from Ba/F3 cells expressing EML4-ALK or EML4-ALK with the L1196M mutation.

PMID 21575866 · Sakamoto et al., 2011 · Open in CIViC

The crizotinib-resistant MGH045 cell line with EML4-ALK L1196M was treated with crizotinib or ceritinib. In nude mice with MGH045 xenografts, tumor response to crizotinib did not differ appreciably fr… (full text at CIViC)

PMID 24675041 · Friboulet et al., 2014 · Open in CIViC

Case report of a patient with metastatic ALK-rearranged NSCLC. After developing resistance to first and second line ALK inhibitors mediated by a C1156Y mutation, the patient had a partial response wit… (full text at CIViC)

PMID 26698910 · Shaw et al., 2016 · Open in CIViC

Case report of a patient with metastatic ALK-rearranged NSCLC. After developing resistance to first and second line ALK inhibitors mediated by a C1156Y mutation, the patient had a partial response wit… (full text at CIViC)

PMID 26698910 · Shaw et al., 2016 · Open in CIViC

Ba/F3 cells expressing the EML4-ALK S1206Y variant were treated with ceritinib, and survival GI50 value of 1.5 nM was obtained, which compares favorably with GI50 of 1.7 for the highly ceritinib sensi… (full text at CIViC)

PMID 24675041 · Friboulet et al., 2014 · Open in CIViC

The S1206Y mutation in the EML4-ALK fusion was found to confer resistance to crizotinib in Ba/F3 cells.

PMID 22277784 · Katayama et al., 2012 · Open in CIViC

Ba/F3 cells expressing EML4-ALK with 1151 Tins treated with alectinib had an IC50 of 165.7 nM, 16x higher than those expressing EML4-ALK wildtype variant 1. EML4-ALK variant 1 expressing H3122 NSCLC c… (full text at CIViC)

PMID 22277784 · Katayama et al., 2012 · Open in CIViC

Treatment of Ba/F3 cells expressing EML4-ALK 1151 insT with TAE684 produced an IC50 value (28.3 nM) 20x higher cells expressing EML4-ALK wildtype variant 1. The crizotinib resistant clones were produc… (full text at CIViC)

PMID 22277784 · Katayama et al., 2012 · Open in CIViC

The EML4 ALK variant 1 containing NSCLC cell line H3122 is highly sensitive to alectinib, and an alectinib resistant derivative cell line H3122 CHR-A1 was generated by incubation of H3122 in increasin… (full text at CIViC)

PMID 25228534 · Katayama et al., 2014 · Open in CIViC

The V1180L mutation in the kinase domain of rearranged ALK was found in an alectinib resistant cell line named H3122 CHR-A1, which was derived from the alectinib sensitive EML4-ALK variant 1 containin… (full text at CIViC)

PMID 25228534 · Katayama et al., 2014 · Open in CIViC

A 45-year-old non-smoking female patient was diagnosed with a stage IV lung adenocarcinoma and magnetic resonance imaging showed multiple brain metastases. Targeted NGS analysis on the pleural biopsy … (full text at CIViC)

PMID 36419889 · Lazzari et al., 2022 · Open in CIViC

The paper mentions a 43-year-old-male with an EML4::NTRK3 rearrangement in metastatic non-small cell lung cancer initially treated with carboplatin/paclitaxel chemotherapy. Upon identification of an … (full text at CIViC)

PMID 34625502 · Murray et al., 2021 · Open in CIViC

A patient with lung adenocarcinoma showed a double ALK fusion, EML6 exon1-ALK exon20 and FBXO11 exon1-ALK exon20. The patient received Crizotinib 250 mg twice daily and eventually showed partial respo… (full text at CIViC)

PMID 30368418 · Lin et al., 2018 · Open in CIViC

In a phase 2 trial, 152 metastatic NSCLC patients harboring mutations in ERBB2 (HER2) treated with 2 different doses of the HER2 ADC trastuzumab deruxtecan (5.4 mg/kg and 6.4 mg/kg) resulted in clinic… (full text at CIViC)

PMID 37694347 · Goto et al., 2023 · Open in CIViC

In a phase 2 trial, 152 metastatic NSCLC patients harboring mutations in ERBB2 (HER2) treated with 2 different doses of the HER2 ADC trastuzumab deruxtecan (5.4 mg/kg and 6.4 mg/kg) resulted in clinic… (full text at CIViC)

PMID 37694347 · Goto et al., 2023 · Open in CIViC

In a phase 2 trial, 152 metastatic NSCLC patients harboring mutations in ERBB2 (HER2) treated with 2 different doses of the HER2 ADC trastuzumab deruxtecan (5.4 mg/kg and 6.4 mg/kg) resulted in clinic… (full text at CIViC)

PMID 37694347 · Goto et al., 2023 · Open in CIViC

Cell proliferation analysis of NIH 3T3 cells harboring the A775_G776insYVMA insertion exhibit an increase of colony formation in soft agar compared with a wild-type ERBB2 and cells with ERBB2 D845A ki… (full text at CIViC)

PMID 22908275 · Greulich et al., 2012 · Open in CIViC

Cell proliferation analysis of NIH 3T3 cells harboring the A775_G776insYVMA insertion exhibit an increase of colony formation in soft agar compared with a wild-type ERBB2 and cells with ERBB2 D845A ki… (full text at CIViC)

PMID 22908275 · Greulich et al., 2012 · Open in CIViC